C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q35041171

about

Recent updates of precision therapy for gastric cancer: Towards optimal tailored management State of the art management of metastatic gastroesophageal cancer From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.Plasma membrane proteomic analysis of human Gastric Cancer tissues: revealing flotillin 1 as a marker for Gastric Cancer.Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.miR-146a Polymorphism (rs2910164) Predicts Colorectal Cancer Patients' Susceptibility to Liver Metastasis.LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy.Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors.The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells.Remodeling of the pulmonary artery induced by metastatic gastric carcinoma: a histopathological analysis of 51 autopsy cases.MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.The expression and clinical significance of miR-132 in gastric cancer patients.MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis.Targeted therapy in gastric cancer.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Monoclonal antibodies for treating gastric cancer: promises and pitfalls.Advanced gastric adenocarcinoma: optimizing therapy options.Novel Targeted Therapies for Esophagogastric Cancer.A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.Occult gastric cancer presenting as hypoxia from pulmonary tumor thrombotic microangiopathy.Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis.Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review.Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review.Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review.Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review.Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment

P2860

Q26746246-FCB31BB8-FE06-4764-A472-87A6D2C94C26 Q26779217-E2EA4277-B326-4B10-A623-6CB138C7EC40 Q28082921-E502F828-BDBB-4ECF-8AF4-9E5D9373EDF9 Q33769437-788217B2-A07B-49F6-BCA3-8317CB731236 Q33917507-6394EE4A-937C-4DAC-A095-A1CB0BDE3DE8 Q35092377-CC3C266B-F6FE-428A-84C6-F2E71180883E Q35623711-CBF2E11E-0E5D-4C65-BECB-FFAC1F9F0500 Q35924247-786CB95A-F40C-407F-AF67-C3230896333E Q35955290-E626AF63-A71F-47C8-B59E-1FB56E1A8EFD Q36185673-6E3A6368-3264-46E7-ACBC-F0488C00311F Q36293805-606FE08D-FD8D-43F0-9BF4-8D4AC3F4AA40 Q36638061-355C130C-FA78-4BCC-B88C-DBC512A0EA74 Q37283371-5187FB6B-8CBA-47C5-BBF1-D68D98E9EA63 Q37302936-36990B28-6620-4A09-B854-467A86362056 Q37342442-205DA55E-2390-4DA9-970D-838AD74070FE Q37376230-FFA2A1B6-83D2-4799-BC34-9F5DB34B252C Q37583006-624FA513-4B76-4825-8BE0-61952B905797 Q37682961-768F5A31-E2A7-47D8-84D0-DC27D5A91562 Q37683714-C3336D24-B7D7-4EF4-83D6-48ED58AF6834 Q37705824-4B29197A-FDF5-4A86-93CA-24CC5CFA37D1 Q38239580-0775B073-8432-41EF-B35F-7D706BEBF98E Q38263575-D3F78B68-E203-4550-A6D5-7B4E1E503405 Q38337913-5216B39B-D983-41B7-851B-B2952EE640B3 Q38364292-0D532A57-77B9-4778-A374-FFC8CAABA282 Q38684349-ABE6B5E0-AB35-4D52-A937-AB4AA98F9437 Q38772049-DAD6B4BC-245A-4C97-BC6C-21DC6A1B27F4 Q39091817-124D39EF-2136-41D1-996C-E2084511B87E Q39171565-1D50C9FC-4F90-4299-A12B-537A9098A868 Q41045405-25084555-0F05-4FA0-94AC-033801EB8260 Q42153359-D36836AC-D09B-4210-82DE-7AE28456E6B2 Q42700697-947C0475-816A-4F37-B935-929165238CBF Q44288144-264BE848-5985-4F66-896F-F2D17A3AB861 Q45968290-2018CC68-AD86-4F11-B10D-AC965FA6BB4C Q47103399-E0B9CDE6-25BE-46EB-807C-38D3AE8D3BE5 Q47139946-4C9C7A68-B6E3-4DC9-A82A-E788D055CD1D Q49414583-EB65EF5C-AC0B-45A7-B438-14F45C8E2687 Q57493808-000E5940-0E45-4742-AABA-893783A46635 Q58783978-6F242AB2-1D5C-4926-A3B2-ABF85FF5D93A

P2860

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q35041171

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

@ast

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

@en

type

label

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

@ast

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

@en

prefLabel

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

@ast

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

@en

P1433

Q35041171-791ED649-F46B-44B2-BD36-FA4FA165B081

P1476

Q35041171-5E54B117-ACA7-4339-BA7F-D274F10C00EB

P2093

Q35041171-52923F92-8E59-46E5-A718-84CE35D63763

Q35041171-71CCCFE2-E7C3-46F5-A18E-3229CDF1287E

Q35041171-8D644788-A182-4596-A1AC-77C366BF1C4E

Q35041171-C62A0A2C-3C43-43F6-A59C-42B31A3640BF

Q35041171-D17D2882-FE6D-4118-972B-705BCEF31CC0

Q35041171-DB6D40FD-5574-4EB8-B26E-2F80360F855F

P275

Q35041171-A5ECBCB5-0512-4E9E-9565-CAFD994F11E2

P2860

Q35041171-01406C57-FBF7-4B33-BF6B-C49256F5BDC6

Q35041171-190B3614-32E1-494E-96D1-2F96A21F2220

Q35041171-19334FEF-5E6A-4C76-A920-D2BF4215E178

Q35041171-19AB7849-E495-4E71-91AE-2F12F6EC65AF

Q35041171-44088934-BFAD-4535-9A4E-E24B3C25BD97

Q35041171-4AFBB536-CDD7-4500-829E-032670F24BBE

Q35041171-514FB24D-3A60-47ED-90D8-7D40E7F16AB1

Q35041171-533E4DC5-5357-472C-A480-8E485617B11B

Q35041171-5676CCAA-3FF7-40ED-A56E-80E21D44E969

Q35041171-6EFBFD3D-CB09-4683-B999-4D120B19F29E

P304

Q35041171-DD6B163C-0C96-4164-9587-C2BAE25D6E60

P31

Q35041171-C76982C9-3604-4D8E-BC7D-2026D9725FC9

Q35041171-EF57451A-2331-458E-8DEE-D14C4201C352

Q35041171-cbd2c606-7ae3-411b-b495-9236130b3e42

P356

Q35041171-6DACBA71-3F6B-4004-A99F-6FD7B0CF8115

P407

Q35041171-695B46FF-CBF1-497F-9FED-02D06ABA6342

P433

Q35041171-F85E4D6F-83A2-4368-9DAA-F110BB468A00

P478

Q35041171-BFAE9B79-5985-4FB8-8A84-26DD5C40B233

P5008

Q35041171-237FFCB7-D9A8-47B9-ADA3-C947656A6167

P577

Q35041171-FD7F2B62-CEB6-4F02-AC3D-D89E211783F6

P5875

Q35041171-3EEA74AA-D817-4C9F-8ED7-148D178AEADF

P698

Q35041171-DC67E182-33F8-47B9-A51B-12BA9B0D972C

P921

Q35041171-1B992F72-CB78-4274-9C67-6CED79072CE0

Q35041171-2C0D97AC-7434-4989-B665-5031C5F9B567

Q35041171-3E0D8C55-E86B-4C60-907D-5566DD01CEFB

Q35041171-466A156C-7F4F-445C-AE93-374A25B8F7E1

Q35041171-530F7FE3-78C9-47CF-B9C0-D189D84A7117

Q35041171-6E16C85D-3441-485E-A2A2-B6328C27C332

Q35041171-8FFCC898-D4E6-4CAD-828A-09F322E61FFA

Q35041171-A9D39ED7-363A-4E6E-9A73-79CB343A5562

P932

Q35041171-294EB4D0-CAF5-4C2E-80CD-A0EF60E08D8E

P356

JOURNAL.PONE.0079137

P1433

P1476

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.

@en

P2093

Jianlan Cui

http://www.w3.org/2001/XMLSchema#string

Naiqing Zhao

http://www.w3.org/2001/XMLSchema#string

Shan Yu

http://www.w3.org/2001/XMLSchema#string

Tianshu Liu

http://www.w3.org/2001/XMLSchema#string

Wei Li

http://www.w3.org/2001/XMLSchema#string

Yiyi Yu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Global cancer statistics

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Sema4D induces angiogenesis through Met recruitment by Plexin B1

Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.

Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue.

P304

e79137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0079137

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258504994

http://www.w3.org/2001/XMLSchema#string

P698

24223894

http://www.w3.org/2001/XMLSchema#string

P921

stomach neoplasm

cell surface receptor

membrane proteins

proto-oncogene proteins

tumor biomarkers

neoplasm proteins

P932

3817069

http://www.w3.org/2001/XMLSchema#string